Garnet BioTherapeutics is a clinical stage regenerative medicine company located in Malvern, PA. Garnet’s mission is to discover, develop, and deliver new regenerative therapies by leveraging the intrinsic ability of adult somatic cells to repair, regenerate, and remodel tissue in acute and chronic disease settings.
The company’s broad technology platform has been set up to maximize success by leveraging the company’s expertise in cell manufacture and clinical development. The challenge of scale-up has been addressed by developing proprietary technology to meet market needs and enable the manufacture of billions of doses from a single donor tissue at low cost. The company has identified a distinct population of bone marrow-derived stromal cells that, when placed in an area of injury, elaborate many pro-healing and anti-inflammatory factors in the area around them. The cells have been demonstrated to produce a plethora of factors, which in addition to directly aiding the wound, recruit endogenous cells to the area to aid in repair and regeneration.
Garnet’s manufacturing process is also adaptable to other cells types, including chondrocytes, smooth muscle cells, skeletal muscle cells, neural progenitors, and fibroblasts, to name only a few. Two therapeutic platforms have been developed: a liquid suspension of cells stored in the vapor phase of liquid nitrogen prior to use (GBT009), and bioactive, non-living cell-based devices.